CMMB today
$1.19+$0.05 (+4.39%)close Nov 20, 2026Trend
DailyDowntrend (confirmed)
4 hourAscending Triangle
1 hourExpanding
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $2.99
Key levels
Resistance$1.42
Resistance$1.21
Support$0.92
Latest news & SEC filings
DealSEC clears registration filing tied to Chemomab Therapeutics' planned merger with Scipher Medicine
DealChemomab says SEC clears Scipher Medicine merger registration, vote set for December 4
All CMMB news →About Chemomab Therapeutics
Chemomab Therapeutics develops antibody-based medicines for conditions involving tissue scarring and persistent inflammation. Its main candidate, nebokitug, targets the protein CCL24 and is being tested mainly in primary sclerosing cholangitis and systemic sclerosis, two rare diseases. The company is based in Israel and also has a presence in the United States.
Based on the company's 20-F filed Mar 23, 2026.
Nasdaq · Healthcare
Chemomab Therapeutics Ltd. (CMMB)
What Is the Price Target for CMMB?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is CMMB a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
Test your own strategy on CMMB
Describe your strategy in plain words, then scan, alert, backtest and paper trade it on CMMB with SEPT’s own market data.
Start Free Trial →Is CMMB Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
12
Moat Score
NONE
3/9
Piotroski Score
284.0
Altman Z-Score
What Is Smart Money Doing with CMMB?
Insider Signal
NEUTRAL
2 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Mor George Adi | director officer | Sale | 4,878 | $10K | May 29, 2026 |
| Mor George Adi | director officer | Sale | 4,926 | $10K | May 29, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See Smart Money Data →CMMB Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-53.85%
FCF Growth YoY
27.6%
Revenue Trend
UNKNOWN
Dark Pool Trades for CMMB
PREVIEWRecent off-exchange (dark pool) prints for CMMB: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:58:07 | $1.22 | 1,838 | $$2K | BUY |
| 20:56:09 | $1.21 | 1,000 | $$1K | SELL |
| 20:44:48 | $1.20 | 1,001 | $$1K | MIDPOINT |
| 20:21:57 | $1.20 | 1,000 | $$1K | SELL |
| 18:30:07 | $1.25 | 2,211 | $$3K | BUY |
5 dark pool trades shown · $$9K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Chemomab Therapeutics Ltd. (CMMB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Your strategy, tested before real money.
Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.
Try SEPT Free for 7 Days →CMMB — frequently asked questions
What is CMMB stock price today?
Chemomab Therapeutics Ltd. (CMMB) is at $1.19, up 4.39% (+$0.05) at the Nov 20, 2026 close.
Why is CMMB stock moving today?
Latest CMMB news — Nov 3, 2026: SEC clears registration filing tied to Chemomab Therapeutics' planned merger with Scipher Medicine · Nov 2, 2026: Chemomab says SEC clears Scipher Medicine merger registration, vote set for December 4
Did CMMB beat earnings?
CMMB last reported on Aug 19, 2026: EPS -$0.27 vs -$0.15 expected — a miss of 80.0%.
What are CMMB support and resistance levels?
Support: $0.92. Resistance: $1.21, $1.42, $1.72.
What are insiders doing with CMMB?
Insider activity: NEUTRAL, 2 buys and 0 sells in the last 90 days.
What is the latest news on CMMB?
Nov 3, 2026: SEC clears registration filing tied to Chemomab Therapeutics' planned merger with Scipher Medicine · Nov 2, 2026: Chemomab says SEC clears Scipher Medicine merger registration, vote set for December 4